

FROM R&D EXPERTISE TO CLINICAL INNOVATION

mAbXmise is an innovation born from the combination of **Promise Proteomics'** recognized expertise in mass spectrometry and its unique know-how in the production of internal standards for proteins assays.

Today this innovative range is available in clinical practice to assist healthcare professionals in their decision making.

mAbXmise References	Designation	Packaging
INF-TDM-01	mAbXmise Inflammation	96 wells
ONC-TDM-01	mAbXmise Oncology	96 wells
GFT-TDM-01	mAbXmise Transplantation	96 wells

REFERENCES AND PUBLICATIONS

[1] Marin, C.; et al. Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals 2021

Millet A, Khoudour N, Guitton J, Lebert D, Goldwasser F, Blanchet B, Machon C. Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa. Biomedicines. 2021 May 30

Millet A, Khoudour N, Lebert D, Machon C, Terrier B, Blanchet B, Guitton J. Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human Plasma. Molecules. 2021 Mar 4

Millet A, Khoudour N, Bros P, Lebert D, Picard G, Machon C, Goldwasser F, Blanchet B, Guitton J. Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA. Talanta. 2021 Mar 1

Millet A, Lebert D, Picard G, You B, Ceruse P, Guitton J. Determination of Cetuximab in Plasma by Liquid Chromatography-High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled ¹³C,¹⁵N-Cetuximab Internal Standard. Ther Drug Monit. 2019 Aug

Jourdil JF, Lebert D, Gautier-Veyret E, Lemaitre F, Bonaz B, Picard G, Tonini J, Stanke-Labesque F. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods? Anal Bioanal Chem. 2017 Feb

Lebert D, Picard G, Beau-Larvor C, Troncy L, Lacheny C, Maynadier B, Low W, Mouz N, Brun V, Klinguer-Hamour C, Jaquinod M, Beck A. Absolute and multiplex quantification of antibodies in serum using PSAQ™ standards and LC-MS/MS. Bioanalysis. 2015

Broué, F. (2022). Advantages of monitoring biotherapies in oncology. La Lettre du Cancérologue, 90-91.

Legal mention : PROMISE Proteomics products are distributed globally, so uses, applications, and availability of product in each country depend on local regulatory registration status. Products of diagnostic portfolio are not registered in the United States. Products not registered and all other products are For Research Use Only.

promise
PROTEOMICS



www.mabxmise.com
www.promise-proteomics.com



PROMISE PROTEOMICS SAS

7, parvis Louis Néel • BHT 52 A • CS 20050
38040 Grenoble Cedex 9 • FRANCE
Phone +33 4 38 02 36 50
contact@promise-proteomics.com

RCS Grenoble B 433 546 504

mAbXmise

New generation of biotherapies monitoring
by mass spectrometry



PROM-0001V01-06-22-EN

DEVELOPED BY
promise
ADVANCED PROTEOMICS

A UNIQUE TECHNOLOGY FOR TDM OF BIOTHERAPIES

mAbXmise determines the plasma concentration of monoclonal antibodies.

Its unique technology is based on the combination of internal standards labeled with stable isotopes (SIL-mAb) and mass spectrometry analysis. It allows multiplex measurement with high analytical performance.

Healthcare professionals can then use the information to personalize treatment, adjust dosages and reduce treatment costs^[1].



HIGH PERFORMANCE & EASE OF USE

PATENTED TECHNOLOGY combining mass spectrometry & isotope stable labeled monoclonal antibodies (SIL-mAbs) for absolute quantification

HIGH SPECIFICITY provided by LC-MS

MULTIPLEX KITS up to 7 mAbs at once

READY-TO-USE with ready to use reagents and standardized protocols

INCLUDED IN EACH KIT

- 96-well plate coated with stable labeled mAbs (internal standards)
- 6 calibrators
- 2 QC
- Relevant buffers and solutions
- Specific consumables
- Protease

CE-IVD KITS TO MEASURE BLOOD CONCENTRATIONS OF THERAPEUTIC MONOCLONAL ANTIBODIES

ONCOLOGY

1 KIT for 7 mAbs

- Bevacizumab
- Cetuximab
- Rituximab
- Trastuzumab
- Nivolumab
- Pembrolizumab
- Ipilimumab

INFLAMMATION

1 KIT for 2 mAbs

- Infliximab
- Adalimumab

TRANSPLANTATION

1 KIT for 2 mAbs

- Belatacept
- Abatacept

A STEP BY STEP APPROACH, FROM SAMPLE TO RESULT




1. Plasma sample




2. Sample purification



3. Enzymatic digestion



4. LC-MS/MS analysis



5. Reliable and accurate quantification

